Shunxi Private Equity Fund Management

Shunxi Private Equity Fund Management is a Chinese private equity firm that focuses on investing in a diverse range of sectors, including technology and healthcare. The firm manages multiple funds, such as Shunxi I, Shunxi II, and Shunxi III, each with specific investment focuses and fund sizes. Shunxi I, established in 2015, primarily invests in technology innovation and healthcare, with a fund size of RMB 228.29 million. Shunxi II, launched in 2018, has a fund size of RMB 140 million and also concentrates on technology innovation and healthcare. Shunxi III, initiated in 2021, targets a fund size of RMB 2.22 billion, focusing on technology innovation and healthcare.

The firm's investment strategy involves providing capital to companies in various stages, including early-stage, growth, late-stage, pre-IPO, and buyout opportunities. Shunxi Private Equity Fund Management has a history of investing in sectors such as biotechnology, pharmaceuticals, medical devices, artificial intelligence, robotics, semiconductors, manufacturing, consumer goods, media, entertainment, education, financial services, and logistics. Notable investments include Beijing Scitop Bio-tech Co., Ltd., which was listed on the Shenzhen Stock Exchange in July 2020, and Beijing Bayuegua Technology Co., Ltd., a leading technology service company specializing in big data and cloud-computing technologies.

The firm's portfolio reflects a commitment to supporting innovative companies across various industries, aiming to foster growth and development in sectors critical to China's economic advancement. Shunxi Private Equity Fund Management's strategic investments are designed to leverage emerging opportunities in technology and healthcare, contributing to the evolution of these dynamic sectors within the Chinese market.